anpc - ANPC STOCK NEWS

AnPac Bio, a biotechnology company focused on early cancer screening and detection, announced its ranking as number one in global multiple cancer screening volume by Frost & Sullivan. The report indicates AnPac Bio conducted 216,600 detection tests, surpassing GRAIL Company, which ranked second with 135,100 tests. AnPac Bio has been a pioneer in this field, holding 150 patents as of September 2021. The company’s CDA technology detects over 20 cancer types with high sensitivity, showcasing its commitment to innovative cancer detection solutions.

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) has received a Notification Letter from Nasdaq indicating non-compliance with the minimum Market Value of Publicly Held Shares (MVPHS) requirement of $15 million. This deficiency occurred over 30 consecutive business days from December 3, 2021, to January 18, 2022. AnPac Bio has a compliance period until July 18, 2022, to rectify this issue. Additionally, the company faces a separate deficiency regarding the Market Value of Listed Securities (MVLS) of $50 million, with a deadline of March 23, 2022. The company’s business operations remain unaffected.

AnPac Bio-Medical Science Co., Ltd. (ANPC) announced a significant milestone on January 4, 2022, as its Class III medical device for lung cancer auxiliary diagnosis successfully passed registration tests mandated by China's National Medical Products Administration (NMPA) on December 30, 2021. This advancement is pivotal for the company’s goal of obtaining the Class III registration certificate, allowing access to the medical market for lung cancer diagnosis. Clinical trials are set to commence in Q1 2022, following extensive testing since the registration process began in December 2018.

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) announced the publication of a technical paper on its Cancer Differentiation Analysis (CDA) Technology, which facilitates multi-cancer screening. Published on November 30, 2021, in the Expert Review of Molecular Diagnostics, the paper highlights findings from extensive clinical studies involving over 75,000 individuals. CDA technology is noted for its high specificity, moderate sensitivity, and cost-effectiveness. The company anticipates receiving a Class III medical device license by late 2022, enhancing its cancer detection capabilities.

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) reported a 55.3% revenue increase to approximately RMB13.7 million (US$2.1 million) for the nine months ending September 30, 2021. The gross profit margin rose to 59.3%, up from 50.5% in the previous year, attributed to higher selling prices for cancer tests. However, the net loss widened to about RMB89.0 million (US$13.8 million), compared to RMB69.5 million in 2020, affected by an unrealized loss on convertible debt. The company has 5.5 million cash reserves as of September 30, 2021.

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) announced a public offering of American Depositary Shares priced at $2.22 each, aiming to raise approximately $2.5 million. The offering includes 1,132,111 shares, with an option for underwriters to purchase an additional 169,817 shares within 45 days. The expected closing date for the offering is November 15, 2021. This announcement corrects earlier information regarding the offering's dollar size and share count, emphasizing the inclusion of the over-allotment option.

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) has announced the pricing of an underwritten public offering of 1,301,928 American Depositary Shares at $2.22 per share, aimed at raising approximately $2.9 million before expenses. The offering includes the full exercise of the underwriter’s over-allotment option and is expected to close around November 12, 2021. AnPac Bio, which specializes in early cancer screening and detection with a significant number of patents and clinical samples, is leveraging this funding to enhance its operations in the biotechnology sector.

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) has announced an underwritten public offering of its American Depositary Shares. The offering will be managed by EF Hutton and is subject to market conditions. A registration statement was filed with the SEC in May 2021 and became effective in June 2021. The offering aims to raise capital for the company's operations focused on early cancer screening and detection, where AnPac Bio has developed several patented technologies. The company ranks third globally in next-generation cancer screening technologies as of 2019.

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) has announced an underwritten public offering of its American Depositary Shares (ADSs), managed by EF Hutton. The offering is subject to market conditions, with no assurance regarding completion or terms. AnPac Bio focuses on early cancer screening and detection, holding 148 patents as of June 30, 2021. The company ranks third globally in next-generation screening technologies. Its CDA technology can detect over 20 cancer types. A registration statement for the offering was filed with the SEC in May 2021.